手术视频
关于我们
联系我们
中心官网
泌尿系统常见疾病循证医学证据
首页
良性前列腺增生
泌尿系统感染
泌尿系统结石
前列腺炎
前列腺癌
膀胱肿瘤
肾癌
其他
首页
搜索结果
证据分类
良性前列腺增生
病因/危险因素证据
诊断证据
治疗及预后证据
预防证据
临床路径
临床实践指南
手术视频
调查问卷
泌尿系统感染
病因/危险因素证据
诊断证据
治疗及预后证据
预防证据
临床路径
临床实践指南
泌尿系统结石
病因/危险因素证据
诊断证据
治疗及预后证据
预防证据
临床路径
临床实践指南
前列腺炎
病因/危险因素证据
诊断证据
治疗及预后证据
预防证据
临床路径
临床实践指南
前列腺癌
病因/危险因素证据
诊断证据
治疗及预后证据
预防证据
临床路径
临床实践指南
膀胱肿瘤
病因/危险因素证据
诊断证据
治疗及预后证据
预防证据
临床路径
临床实践指南
肾癌
病因/危险因素证据
诊断证据
治疗及预后证据
预防证据
临床路径
临床实践指南
其他
病因/危险因素证据
诊断证据
治疗及预后证据
预防证据
临床路径
临床实践指南
搜索结果
按作者
按标题
按关键词
按摘要
按作者
按期刊
共搜索到
7条
与
Kulkarni G. S.
有关的结果
Robotic Versus Open Cystectomy for Bladder Cancer: Synthesizing the Data from Current Systematic Reviews and Meta-Analyses
2023 年 发布于
Ann Surg Oncol
40 卷 第 8 期
Aminoltejari K.
Hird A. E.
Klaassen Z.
Satkunasivam R.
Kulkarni G. S.
Luckenbaugh A. N.
Laviana A. A.
Wallis C. J. D.
Clark R.
超声造影
增强CT
膀胱肿瘤
Meta分析
文献简介
原文链接
Diagnosis and Management of Non-Metastatic Upper Tract Urothelial Carcinoma: AUA/SUO Guideline
2023 年 发布于
J Urol
209 卷 第 6 期
Coleman J. A.
Clark P. E.
Bixler B. R.
Buckley D. I.
Chang S. S.
Chou R.
Hoffman-Censits J.
Kulkarni G. S.
Matin S. F.
Pierorazio P. M.
Potretzke A. M.
Psutka S. P.
Raman J. D.
Smith A. B.
Smith L.
文献简介
原文链接
Open vs. robot-assisted radical cystectomy with extracorporeal or intracorporeal urinary diversion for bladder cancer A pairwise meta-analysis of outcomes and a network meta-analysis of complications
2023 年 发布于
Can Urol Assoc J
24 卷 第 1 期
Riveros C.
Ranganathan S.
Nipper C.
Lim K.
Brooks M.
Dursun F.
Miles B. J.
Goh A. C.
Desai M.
Klaassen Z.
Kulkarni G. S.
Wallis C. J. D.
Satkunasivam R.
bladder cancer
germline
monogenic gene
pathogenic mutations
risk
文献简介
原文链接
Canadian Urological Association guideline on the management of non-muscle-invasive bladder cancer - Full-text
2021 年 发布于
Can Urol Assoc J
15 卷 第 8 期
Bhindi B.
Kool R.
Kulkarni G. S.
Siemens D. R.
Aprikian A. G.
Breau R. H.
Brimo F.
Fairey A.
French C.
Hanna N.
Izawa J. I.
Lacombe L.
McPherson V.
Rendon R. A.
Shayegan B.
So A. I.
Zlotta A. R.
Black P. C.
Kassouf W.
Guidelines as Topic
Humans
Immunotherapy/*methods
Societies
Medical/*standards
Urinary Bladder Neoplasms/*drug therapy
antineoplastic protocols
immunotherapy
urinary bladder neoplasms
urologic neoplasms
Pfizer
AstraZeneca
Nektar
Seattle Genetics
DragonFly Therapeutics
Non-CME
services: Genentech
AstraZeneca
Merck
Seattle Genetics
Contracted research:
Genentech
Merck
AstraZeneca
Nektar
Seattle Genetics
Immunomedics.
PCB─Consulting fees: AbbVie
Asieris Pharmaceuticals
Astellas
AstraZeneca
Bayer
Biosyent
Bristol-Myers Squibb
EMD Serono
Ferring
Fergene
H3
Biomedicine
Janssen
Merck
Roche
Sanofi
TerSera
Urogen
Contracted research:
iProgen. MTC─Consulting fees: Pfizer
EMD Serono
AstraZeneca
Exelixis
Eisai
Seattle Genetics
Astellas
Contracted research: Exelixis
Pfizer/EMD Serono
Janssen
Apricity Health. GSD─Participant/unpaid volunteer: HealthVibe focus
group 2020. MDG─Consulting fees: Inovio
NuMab
Janssen
Merck
GlaxoSmithKline
Genentech
Bristol-Myers Squibb
Seattle Genetics
Dracen
Dragonfly
Astellas
Novartis
Pfizer
AstraZeneca
Incyte
Dendreon
Eli Lilly
EMD Serono
Aileron
Therapeutics
Ownership interest: Rappta Therapeutics
NPI: 1639140668.
PG─Consulting fees: AstraZeneca
Dyania Health
EMD Serono
Immunomedics
Janssen
Merck
Mirati Therapeutics
Genentech
Pfizer
Seattle Genetics
Contracted Research: Bavarian Nordic
Bristol-Myers Squibb
Clovis Oncology
Debiopharm
Immunomedics
Pfizer
Merck
QED Therapeutics
GlaxoSmithKline
Kure
It Cancer Research
Mirati Therapeutics. SG─Consulting fees: Merck
Bristol-Myers
Squibb
Janssen
Seattle Genetics
AstraZeneca
Contracted research:
Bristol-Myers Squibb
Pfizer
Non-CME services: Exelixis. CJH─Consulting fees:
Astellas
Bristol-Myers Squibb
Genentech
Merck
Eisai
Seattle Genetics
2bPrecise
Non-CME services: Astellas
Bristol-Myers Squibb
Genentech
Eisai
Seattle Genetics. AMK─Consulting fees: Abbott Molecular
Arquer
ArTara
Asieris
AstraZeneca
BioClin Therapeutics
Bristol-Myers Squibb
Cepheid
Cold Genesys
Eisai
Engene
Inc.
Ferring
FerGene
Imagin
Janssen
MDxHealth
Medac
Merck
Pfizer
Photocure
ProTara
Roviant
Seattle Genetics
Sessen Bio
Theralase
TMC
Innovation
US Biotest
Contracted research: Adolor
Bristol-Myers Squibb
FKD
Industries
Heat Biologics
Merck
Photocure
SWOG/NIH
SPORE
AIBCCR
Clinical
trials: FKD
Merck
Bristol-Myers Squibb
Photocure
SWOG
Adolor
Heat
Biologics
Laboratory research: NIH
SPORE
AIBCCR
Educational grant: CEC
Oncology
Editorial board: European Urology Oncology
Journal of Urology
UroToday
President of organization: International Bladder Cancer Network (IBCN)
International Bladder Cancer Group (IBCG)
IP Rights: CyPRIT (Cytokine Predictors
of Response to Intravesical Therapy) Joint with UT MD Anderson Cancer Center.
LPL─Consulting fees: Pfizer Advisory Nursing board
2018
Lecture/Speaker/Expert
Panel: ASCO Bladder Program 2019
Pfizer learning day 2019
ASCO Bladder Program
Panel Member and Faculty 2019
Pfizer Learning Day Speaker 2019
BCAN Webinar
Faculty 11/2020. JJM─Consulting fees: AstraZeneca
Ferring
Janssen
Nucleix
Foundation Medicine
Contracted research: Epizyme
Tesaro
Abbvie
Teaching an
endoscopy course: Olympus. ERP─Consulting fees: AstraZeneca
Infinity Pharma
Pfizer
Flatiron
Genentech
Merck
Seattle Genetics
Contracted research:
Astellas
Bristol-Myers Squibb
Genentech
Merck. JER─Consulting fees: Merck
Bristol-Myers Squibb
AstraZeneca
Astellas
Seattle Genetics
Boehringer
Ingelheim
Bayer
Pfizer
Roche/Genentech
Mirati
QED Therapeutics
Janssen
Pharmacyclics
GlaxoSmithKline
Contracted research/Clinical trial funding:
Seattle Genetics
Astellas
Roche/Genentech
Bayer
AstraZeneca
QED
Therapeutics. NS─Consulting fees: Amgen
Astellas
AstraZeneca
Bayer
Bristol-Myers Squibb
Dendreon
Fergene
Ferring
Janssen
Merck
Myovant
Nymox
Pfizer
Sanofi/Genzyme
Sesen Bio
Sun Pharma
Tolmar. GDS─Consulting fees:
Merck
Janssen
Ferring
Bristol-Myers Squibb
Pfizer
Genentech
Epivax
Oncology
AstraZeneca
Fidia
Cold Genesys
EnGene Bio
Aduro Biotech
Dendreon
FKD Therapies
CiClomed
Seattle Genetics
Urogen
PhotoCure. SITC staff:
SMW—Shares owned: Pacific Biosciences
Editas Medicine
EG
AK
BL
LL─Nothing to
disclose.
文献简介
原文链接
Evidence-based Assessment of Current and Emerging Bladder-sparing Therapies for Non-muscle-invasive Bladder Cancer After Bacillus Calmette-Guerin Therapy: A Systematic Review and Meta-analysis
2020 年 发布于
European Urology Oncology
39 卷 第 1 期
Kamat A. M.
Lerner S. P.
O'Donnell M.
Georgieva M. V.
Yang M.
Inman B. A.
Kassouf W.
Boorjian S. A.
Tyson M. D.
Kulkarni G. S.
Chang S. S.
Konety B. R.
Svatek R. S.
Balar A.
Witjes J. A.
Periodontal diseases
cohort studies
meta-analysis
periodontitis
urinary bladder neoplasms
文献简介
原文链接
Systematic review and meta-analysis on trimodal therapy versus radical cystectomy for muscle-invasive bladder cancer: Does the current quality of evidence justify definitive conclusions?
2019 年 发布于
Current Opinion in Urology
26 卷 第 6 期
Wettstein M. S.
Rooprai J. K.
Pazhepurackel C.
Wallis C. J. D.
Klaassen Z.
Uleryk E. M.
Hermanns T.
Fleshner N. E.
Zlotta A. R.
Kulkarni G. S.
Female
Humans
Male
Prospective Studies
Sex Factors
Urinary Bladder Neoplasms/*etiology
Urinary Tract Infections/*complications
Bladder cancer
Cystitis
Urinary bladder neoplasms
Urinary tract infections
Urothelial carcinoma
文献简介
原文链接
Systematic Review of Factors Associated with the Utilization of Radical Cystectomy for Bladder Cancer
2019 年 发布于
Front Oncol
201 卷 第 6 期
Williams S. B.
Hudgins H. K.
Ray-Zack M. D.
Chamie K.
Smaldone M. C.
Boorjian S. A.
Daneshmand S.
Black P. C.
Kamat A. M.
Goebell P. J.
Seiler R.
Schmitz-Drager B.
Nawroth R.
Baillargeon J.
Klaassen Z.
Kulkarni G. S.
Kim S. P.
Lee E. K.
Holzbeierlein J. M.
Hollenbeck B. K.
Gore J. L.
Biomarkers
Tumor/*urine
Cystoscopy/methods
*DNA Methylation
Humans
Urinary Bladder Neoplasms/*diagnosis/urine
biomarkers
methylation
molecular diagnostics
neoplasms
urinary bladder
urine analysis
文献简介
原文链接